据港交所2月12日披露，深圳信立泰（002294）药业股份有限公司(简称：信立泰，002294.SZ)向港交所 主板递交上市申请书，高盛、花旗、中信证券为其联席保荐人。 | [編纂]的 : [編纂]股H股(視乎[編纂]行使與否而定) | | --- | | [編纂]數目 | | [編纂]數目 :[编纂]H股(可予[編纂]) | | [編纂]數目 : [編纂]股H股(可予[編纂]及視乎[編纂]行使 | | 與否而定) | | 最高[編纂] : 每股H股[編纂]港元,另加[編纂]([編纂]) | | 面值 : 每股H股人民幣1.00元 | | [編纂] : [編纂] | 公司简介 据招股书，该公司是中国心血管-肾脏-代谢(心肾代谢综合征)疾病治疗领域的先行者。根据弗若斯特沙利 文的资料，2024年该公司是按收入规模计中国心血管创新药领域第二大的制药企业。截至最后实际可行 日期(2026年2月4日)，根据弗若斯特沙利文的资料，该公司拥有按规模计国内企业中第二大的心肾代谢 综合征创新药管线。该公司的产品组合以创新药为战略核心，同时涵盖仿制药、生物类似药及医疗器 械，相互协同以满足心肾代谢综合征领域巨大未被满足的医疗需 ...

| [編纂]的 : [編纂]股H股(視乎[編纂]行使與否而定) | | --- | | [編纂]數目 | | [編纂]數目 : [编纂]H股(可予[編纂]) | | [編纂]數目 : [編纂]股H股(可予[編纂]及視乎[編纂]行使 | | 與否而定) | | 最高[編纂] 每股H股[編纂]港元,另加[編纂](「編纂]) .. | | 面值 : 每股H股人民幣1.00元 | | [編纂] : [編纂] | 据港交所2月12日披露，深圳信立泰药业股份有限公司(简称：信立泰，002294.SZ)向港交所主板递交上 市申请书，高盛、花旗、中信证券为其联席保荐人。 公司简介 据招股书，该公司是中国心血管-肾脏-代谢(心肾代谢综合征)疾病治疗领域的先行者。根据弗若斯特沙利 文的资料，2024年该公司是按收入规模计中国心血管创新药领域第二大的制药企业。截至最后实际可行 日期(2026年2月4日)，根据弗若斯特沙利文的资料，该公司拥有按规模计国内企业中第二大的心肾代谢 综合征创新药管线。该公司的产品组合以创新药为战略核心，同时涵盖仿制药、生物类似药及医疗器 械，相互协同以满足心肾代谢综合征领域巨大未被满足的医疗需求。 心肾代 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. 深圳信立泰藥業股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同 意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據送呈香港公司註冊處處 長登記的本公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根 據本文件中的資料作出任何投資決定； (b) 在聯交所網站登載 ...

Group 1: Market Strategy - Multiple favorable factors have boosted the market, signaling a recovery in the major indices [5][6] - The overall A-share market saw a rise of 1.04%, with the Shanghai Composite Index increasing by 0.54% to close at 3924.08 points [6][7] - The technology sector, particularly the computing hardware and semiconductor industries, showed strong performance, while blue-chip stocks lagged behind [6][9] Group 2: Economic Insights - The Central Political Bureau of the Communist Party of China held a meeting to analyze and study the economic work for 2026, emphasizing a stable and progressive approach to economic governance [15][16] - November exports (in USD) increased by 5.9% year-on-year, exceeding market expectations, while imports grew by 1.9% [20][21] - The People's Bank of China conducted a 122.3 billion yuan reverse repurchase operation, indicating a proactive monetary policy stance [22][23] Group 3: Industry Dynamics - Youku launched a new cooperative model for online story films, allowing content providers to receive 100% of membership viewing revenue during the revenue-sharing period [24][25] - The National Energy Administration reported seven cases of violations in the open access of the power grid, aiming to enhance service levels for power grid access [26][27] Group 4: Company Updates - Xintai (002294.SZ) announced that its drugs, including Xinchao and Fulian, have been included in the National Medical Insurance Directory, which is expected to enhance their market presence [28][29] - Liyuanheng (688499.SH) signed a strategic cooperation agreement with Quintus Technologies to jointly develop core technologies for solid-state batteries, marking a significant step in the new energy equipment sector [31][32]

Core Insights - Xintai achieved operating revenue of 1.11 billion yuan in Q3, representing a year-on-year growth of 15.85% [1] - The company's net profit after deducting non-recurring items reached 220 million yuan, with a year-on-year increase of 34.75% [1] - The sales structure shows an increase in revenue from new products, which has become the core driver of the company's growth [1] Financial Performance - Q3 operating revenue: 1.11 billion yuan, up 15.85% year-on-year [1] - Net profit (deducting non-recurring items): 220 million yuan, up 34.75% year-on-year [1] Product Development - The company focuses on the CKM (Cardio-Kidney-Metabolic) chronic disease sector, continuously enriching its pipeline of innovative products [1] - Newly launched products, Xinchao Tuo and Fuli An®, are undergoing review through national medical insurance negotiations [1] - The product Enna Luo® is positioned to enhance brand differentiation and expand into both dialysis and non-dialysis patient markets [1] Future Outlook - Increased promotion of new products and innovation R&D efforts have led to a continuous rise in cash outflows related to operating activities [1] - Anticipation of significant growth in innovative product sales due to changes in sales structure and multiple new product approvals [1] - Adjusted earnings forecasts with a target price of 61.77 yuan per share, corresponding to PE ratios of 105/88/72X for November 27, 2025 [1] - Maintained a "Buy" rating for the stock [1]

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported a revenue of 1.11 billion yuan for the third quarter, representing a year-on-year growth of 15.85%, and a net profit of 220 million yuan, up 34.75% year-on-year [1][2] - The sales structure has shifted towards new products, which are now the core driver of the company's growth, particularly in the CKM (Cardio-Renal-Metabolic) chronic disease sector [2][3] - The company is actively preparing for negotiations related to new products that have passed national medical insurance negotiations, enhancing its market coverage through a multi-channel sales strategy [2][3] Financial Projections - Revenue projections for 2025-2027 are adjusted to 4.5 billion, 5.4 billion, and 6.5 billion yuan, reflecting year-on-year growth rates of 12%, 21%, and 20% respectively [4] - The net profit forecasts for the same period are 660 million, 790 million, and 950 million yuan, with year-on-year growth rates of 9.5%, 19.1%, and 21.2% [4] - The earnings per share (EPS) are projected to be 0.59, 0.70, and 0.85 yuan for 2025, 2026, and 2027 respectively [4] Product Development and Market Strategy - The company has a robust pipeline with 74 new drugs under development, focusing on CKM chronic diseases, with over 50 projects in the pipeline [3] - The company is exploring digital chronic disease management models to enhance patient compliance and blood pressure control, thereby increasing its brand influence in the chronic disease market [3] - A dedicated team is being formed for the promotion of new products to improve market penetration [2][3]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company achieved a revenue of 1.11 billion yuan in Q3 2025, representing a year-on-year growth of 15.85%, and a net profit of 216 million yuan, up 30.19% year-on-year. For the first three quarters of 2025, the company reported a revenue of 3.241 billion yuan, a growth of 8%, and a net profit of 581 million yuan, an increase of 13.93% year-on-year [7] - The company is focusing on chronic disease areas, with successful sales expansion. New products have been approved through national medical insurance negotiations, and the company is enhancing market coverage through a multi-channel approach, including e-commerce [7] - The research and development pipeline is robust, with 74 new drugs in development, including 51 chemical drugs and 23 biological drugs. The clinical trials for JK07 are progressing, with expectations for key data release in mid-2026 [7] - The company is projected to achieve revenues of 4.454 billion yuan, 5.344 billion yuan, and 6.253 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 628 million yuan, 690 million yuan, and 796 million yuan [7] Financial Summary - For 2023A, the company reported a revenue of 3,365 million yuan, with a revenue growth rate of -3.4%. The net profit was 580 million yuan, with a net profit growth rate of -9.0% [6] - The projected earnings per share (EPS) for 2025E is 0.56 yuan, with a price-to-earnings (PE) ratio of 89.6 [6] - The return on equity (ROE) is expected to be 7.1% in 2025E, with a price-to-book (PB) ratio of 6.4 [6]

Core Insights - The company reported a revenue of 3.241 billion yuan for the first three quarters of 2025, representing an 8% year-on-year growth [1] - The net profit attributable to shareholders reached 581 million yuan, showing a year-on-year increase of 13.93% [1] Sales Structure - The revenue growth of new products has accelerated, becoming the core driver of the company's development [1] - The company is focusing on the chronic disease field of CKM (cardiovascular and metabolic syndrome) [1] Product Pipeline - The company has continuously enriched its innovative product pipeline [1] - Newly launched products, Xinchao Tuo and Fuli An, have passed the national medical insurance negotiation review, and the company is actively preparing for related negotiations [1]

Core Insights - The company held a roadshow in Shenzhen, attracting over 100 institutions, including IDG Capital and Anxin Fund, to discuss its strategy, R&D progress, and market positioning [1] - The company focuses on chronic disease management (CKM) with a commitment to integrity and long-termism, aiming to become a leader in the treatment of CKM syndromes [2] Financial Performance - In the first half of 2025, the company reported a revenue growth of 4.3% year-on-year, with Q2 showing a significant rebound of 12.3%, and new product revenue accounting for over 50% of total revenue [3] - The company maintains a low debt ratio and substantial cash reserves, with R&D investment consistently above 20% of revenue [3] R&D Pipeline - The company has a robust R&D pipeline in hypertension and related CKM diseases, with various drug types including oral small molecules and combination therapies, some of which are in clinical II/III phases [4] - The company is developing innovative drugs for resistant hypertension, including SAL0140 and SAL0120, and has a focus on improving patient compliance through small nucleic acid products [4][5] Market Strategy - The company has six patented drugs in the hypertension and metabolic disease sectors, with four hypertension products forming a differentiated matrix, two of which are in the medical insurance negotiation phase [6] - The company emphasizes academic promotion and patient education while exploring digital chronic disease management models for comprehensive patient lifecycle management [6] Q&A Highlights - During the Q&A session, the company addressed various market concerns, including the focus on clinical research for JK07, the independent operation of its U.S. subsidiary, and the use of AI to enhance R&D efficiency [7]

Company Strategy - The company focuses on unmet clinical needs, with a commitment to long-term growth and innovation in the cardiovascular-kidney-metabolic (CKM) disease area [4] - It aims to create social value and has established a strong brand in the chronic disease sector, particularly in hypertension and metabolic diseases [4] - The company has six patented drugs targeting hypertension and metabolic diseases, with plans to become the leading brand in hypertension medications in China [4][6] Recent Business Performance - In the first half of 2025, the company's revenue grew by 4.3% year-on-year, with a notable rebound of 12.3% in Q2 [6] - New product revenue now accounts for over 50% of total revenue, indicating successful market penetration [6] - The company maintains a low debt ratio and strong cash reserves, with R&D investment consistently above 20% of revenue [6] R&D Pipeline - The company has 74 new drugs in development, including 51 chemical drugs and 23 biological drugs, with over 50 projects focused on CKM diseases [7] - R&D efforts are supported by platforms in both China and the U.S., utilizing AI to enhance drug discovery and development efficiency [7][8] - The company is developing a comprehensive pipeline for hypertension treatments, aiming for a range of administration methods from daily to quarterly dosing [8] Innovative Drug Development - The company is advancing several first-in-class and best-in-class products for blood lipid management, including a monoclonal antibody for PCSK9 [11] - It is also exploring unique mechanisms for metabolic diseases, focusing on energy metabolism and muscle metabolism to address obesity and diabetes [11][19] - The company is committed to integrating innovation with healthcare policies to ensure rapid clinical application of research outcomes [8] Market Strategy - The company emphasizes academic promotion and patient education to enhance product penetration and disease awareness [14] - It is exploring digital chronic disease management models to improve patient lifecycle management and commercialize chronic disease treatments [14] - The company aims to leverage its products' entry into medical insurance to expand market coverage [14] Clinical Needs and Challenges - Cardiovascular diseases remain the leading cause of death globally, with significant unmet clinical needs in hypertension management [5] - The company recognizes the complexity of hypertension mechanisms and aims to provide tailored treatment solutions for various patient demographics [9][10] - The focus on differentiated strategies in a competitive market is crucial for establishing a unique position in the metabolic disease sector [19]